Proteome analysis in thyroid pathology

References

• Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011;61(2):69-90
   PubMed Web of Science ®Google Scholar
• Cancer Statistics Review, 1975-2011 - SEER Statistics [Internet]. Available from: http://seer.cancer.gov/csr/1975_2011/results_merged/sect_26_thyroid.pdf
   Google Scholar
• Zevallos JP, Hartman CM, Kramer JR, et al. Increased thyroid cancer incidence corresponds to increased use of thyroid ultrasound and fine-needle aspiration: a study of the veterans affairs health care system. Cancer 2014;121(5):741-6
   PubMedGoogle Scholar
• Morris LGT, Sikora AG, Tosteson TD, Davies L. The increasing incidence of thyroid cancer: the influence of access to care. Thyroid Off J Am Thyroid Assoc 2013;23(7):885-91
   PubMedGoogle Scholar
• La Vecchia C, Malvezzi M, Bosetti C, et al. Thyroid cancer mortality and incidence: a global overview. Int J Cancer 2015;136(9):2187-95
   PubMed Web of Science ®Google Scholar
• DeLellis RA, Lloyd RV, Heinz PU, Eng C. Word Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Endocrine Organs. 3rd edition. IARC Press; 2004
   Google Scholar
• Patel KN, Shaha AR. Poorly differentiated thyroid cancer. Curr Opin Otolaryngol Head Neck Surg 2014;22(2):121-6
   PubMed Web of Science ®Google Scholar
• Tzen CY, Huang YW, Fu YS. Is atypical follicular adenoma of the thyroid a preinvasive malignancy? Hum Pathol 2003;34(7):666-9
   PubMedGoogle Scholar
• Vasko VV, Gaudart J, Allasia C, et al. Thyroid follicular adenomas may display features of follicular carcinoma and follicular variant of papillary carcinoma. Eur J Endocrinol Eur Fed Endocr Soc 2004;151(6):779-86
   PubMedGoogle Scholar
• American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer. Cooper DS, Doherty GM, et al. Revised american thyroid association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid Off J Am Thyroid Assoc 2009;19(11):1167-214
   PubMed Web of Science ®Google Scholar
• Polyzos SA, Anastasilakis AD. Clinical complications following thyroid fine-needle biopsy: a systematic review. Clin Endocrinol (Oxf) 2009;71(2):157-65
   PubMed Web of Science ®Google Scholar
• Seningen JL, Nassar A, Henry MR. Correlation of thyroid nodule fine-needle aspiration cytology with corresponding histology at mayo clinic, 2001-2007: an institutional experience of 1,945 cases. Diagn Cytopathol 2012;40(Suppl 1):E27-32
   Google Scholar
• Baier ND, Hahn PF, Gervais DA, et al. Fine-needle aspiration biopsy of thyroid nodules: experience in a cohort of 944 patients. AJR Am J Roentgenol 2009;193(4):1175-9
   PubMedGoogle Scholar
• Rosen JE, Stone MD. Contemporary diagnostic approach to the thyroid nodule. J Surg Oncol 2006;94(8):649-61
   PubMedGoogle Scholar
• Kocjan G, Chandra A, Cross PA, et al. The interobserver reproducibility of thyroid fine-needle aspiration using the UK royal college of pathologists’ classification system. Am J Clin Pathol 2011;135(6):852-9
   PubMed Web of Science ®Google Scholar
• Cibas ES, Ali SZ. The bethesda system for reporting thyroid cytopathology. Thyroid Off J Am Thyroid Assoc 2009;19(11):1159-65
   PubMed Web of Science ®Google Scholar
• Cross PA, Chandra A, Giles T, et al. Guidance on the reporting of thyroid cytology specimens [Internet]. 2009. Available from: www.rcpath.org/Resources/RCPath/Migrated%20Resources/Documents/G/g089guidanceonthereportingofthyroidcytologyfinal.pdf
   Google Scholar
• Bongiovanni M, Crippa S, Baloch Z, et al. Comparison of 5-tiered and 6-tiered diagnostic systems for the reporting of thyroid cytopathology: a multi-institutional study. Cancer Cytopathol 2012;120(2):117-25
   PubMed Web of Science ®Google Scholar
• Pagni F, Prada M, Goffredo P, et al. “Indeterminate for malignancy” (Tir3/Thy3 in the Italian and British systems for classification) thyroid fine needle aspiration (FNA) cytology reporting: morphological criteria and clinical impact. Cytopathol Off J Br Soc Clin Cytol 2014;25(3):170-6
   PubMed Web of Science ®Google Scholar
• Lakhani R, Rourke T, Jefferis A, et al. Thy3 cytology: what to do next? Ann R Coll Surg Engl 2011;93(3):225-8
   PubMedGoogle Scholar
• Calò PG, Medas F, Cruz RS, et al. Follicular nodules (Thy3) of the thyroid: is total thyroidectomy the best option? BMC Surg 2014;14(1):1-7
   PubMedGoogle Scholar
• Baloch ZW, LiVolsi VA, Asa SL, et al. Diagnostic terminology and morphologic criteria for cytologic diagnosis of thyroid lesions: a synopsis of the national cancer institute thyroid fine-needle aspiration state of the science conference. Diagn Cytopathol 2008;36(6):425-37
   PubMed Web of Science ®Google Scholar
• Christou N, Mathonnet M. Complications after total thyroidectomy. J Visc Surg 2013;150(4):249-56
   PubMed Web of Science ®Google Scholar
• Segev DL, Clark DP, Zeiger MA, Umbricht C. Beyond the suspicious thyroid fine needle aspirate. Acta Cytol 2003;47(5):709-22
   PubMedGoogle Scholar
• Haugen BR, Woodmansee WW, McDermott MT. Towards improving the utility of fine-needle aspiration biopsy for the diagnosis of thyroid tumours. Clin Endocrinol (Oxf) 2002;56(3):281-90
   PubMedGoogle Scholar
• Sapio MR, Posca D, Raggioli A, et al. Detection of RET/PTC, TRK and BRAF mutations in preoperative diagnosis of thyroid nodules with indeterminate cytological findings. Clin Endocrinol (Oxf) 2007;66(5):678-83
   PubMed Web of Science ®Google Scholar
• Xing M. Molecular pathogenesis and mechanisms of thyroid cancer. Nat Rev Cancer 2013;13(3):184-99
   PubMed Web of Science ®Google Scholar
• Fischer S, Asa SL. Application of immunohistochemistry to thyroid neoplasms. Arch Pathol Lab Med 2008;132(3):359-72
   PubMedGoogle Scholar
• Rezk S, Khan A. Role of immunohistochemistry in the diagnosis and progression of follicular epithelium-derived thyroid carcinoma. Appl Immunohistochem Mol Morphol AIMM Off Publ Soc Appl Immunohistochem 2005;13(3):256-64
   PubMedGoogle Scholar
• de Matos LL, Del Giglio AB, Matsubayashi CO, et al. Expression of ck-19, galectin-3 and hbme-1 in the differentiation of thyroid lesions: systematic review and diagnostic meta-analysis. Diagn Pathol 2012;7(1):97
   PubMedGoogle Scholar
• Prasad ML, Pellegata NS, Huang Y, et al. Galectin-3, fibronectin-1, CITED-1, HBME1 and cytokeratin-19 immunohistochemistry is useful for the differential diagnosis of thyroid tumors. Mod Pathol Off J U S Can Acad Pathol Inc 2005;18(1):48-57
   PubMed Web of Science ®Google Scholar
• Casey MB, Lohse CM, Lloyd RV. Distinction between papillary thyroid hyperplasia and papillary thyroid carcinoma by immunohistochemical staining for cytokeratin 19, galectin-3, and HBME-1. Endocr Pathol 2003;14(1):55-60
   PubMedGoogle Scholar
• Ersoz S, Sert H, Yandi M, et al. The significance of Galectin-3 expression in the immunocytochemical evaluation of thyroid fine needle aspiration cytology. Pathol Oncol Res POR 2008;14(4):457-60
   PubMedGoogle Scholar
• Raggio E, Camandona M, Solerio D, et al. The diagnostic accuracy of the immunocytochemical markers in the pre-operative evaluation of follicular thyroid lesions. J Endocrinol Invest 2010;33(6):378-81
   PubMedGoogle Scholar
• Saggiorato E, De Pompa R, Volante M, et al. Characterization of thyroid “follicular neoplasms” in fine-needle aspiration cytological specimens using a panel of immunohistochemical markers: a proposal for clinical application. Endocr Relat Cancer 2005;12(2):305-17
   PubMed Web of Science ®Google Scholar
• Saggiorato E, Aversa S, Deandreis D, et al. Galectin-3: presurgical marker of thyroid follicular epithelial cell-derived carcinomas. J Endocrinol Invest 2004;27(4):311-17
   PubMedGoogle Scholar
• Lee WS, Palmer BJA, Garcia A, et al. BRAF mutation in papillary thyroid cancer: a cost-utility analysis of preoperative testing. Surgery 2014;156(6):1569-77. discussion 1577-1578
   PubMedGoogle Scholar
• Mon SY, Hodak SP. Molecular diagnostics for thyroid nodules: the current state of affairs. Endocrinol Metab Clin North Am 2014;43(2):345-65
   PubMedGoogle Scholar
• Cohen Y, Xing M, Mambo E, et al. BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Inst 2003;95(8):625-7
   PubMed Web of Science ®Google Scholar
• Xing M. BRAF mutation in thyroid cancer. Endocr Relat Cancer 2005;12(2):245-62
   PubMed Web of Science ®Google Scholar
• Xing M, Alzahrani AS, Carson KA, et al. Association between BRAF V600E mutation and recurrence of papillary thyroid cancer. J Clin Oncol Off J Am Soc Clin Oncol 2015;33(1):42-50
   PubMed Web of Science ®Google Scholar
• Xing M, Alzahrani AS, Carson KA, et al. Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. JAMA 2013;309(14):1493-501
   PubMed Web of Science ®Google Scholar
• Xing M, Westra WH, Tufano RP, et al. BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab 2005;90(12):6373-9
   PubMed Web of Science ®Google Scholar
• Kim TH, Park YJ, Lim JA, et al. The association of the BRAF(V600E) mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: a meta-analysis. Cancer 2012;118(7):1764-73
   PubMed Web of Science ®Google Scholar
• Nikiforova MN, Kimura ET, Gandhi M, et al. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab 2003;88(11):5399-404
   PubMed Web of Science ®Google Scholar
• Santoro M, Melillo RM, Fusco A. RET/PTC activation in papillary thyroid carcinoma: european journal of endocrinology prize lecture. Eur J Endocrinol Eur Fed Endocr Soc 2006;155(5):645-53
   PubMed Web of Science ®Google Scholar
• Sapio MR, Guerra A, Marotta V, et al. High growth rate of benign thyroid nodules bearing RET/PTC rearrangements. J Clin Endocrinol Metab 2011;96(6):E916-19
   Google Scholar
• Hunt J. Understanding the genotype of follicular thyroid tumors. Endocr Pathol 2005;16(4):311-21
   PubMedGoogle Scholar
• Marotta V, Guerra A, Sapio MR, Vitale M. RET/PTC rearrangement in benign and malignant thyroid diseases: a clinical standpoint. Eur J Endocrinol Eur Fed Endocr Soc 2011;165(4):499-507
   PubMed Web of Science ®Google Scholar
• Eberhardt NL, Grebe SKG, McIver B, Reddi HV. The role of the PAX8/PPARgamma fusion oncogene in the pathogenesis of follicular thyroid cancer. Mol Cell Endocrinol 2010;321(1):50-6
   PubMedGoogle Scholar
• Kroll TG, Sarraf P, Pecciarini L, et al. PAX8-PPARgamma1 fusion oncogene in human thyroid carcinoma [corrected]. Science 2000;289(5483):1357-60
   PubMed Web of Science ®Google Scholar
• Dwight T, Thoppe SR, Foukakis T, et al. Involvement of the PAX8/peroxisome proliferator-activated receptor gamma rearrangement in follicular thyroid tumors. J Clin Endocrinol Metab 2003;88(9):4440-5
   PubMed Web of Science ®Google Scholar
• Alexander EK, Kennedy GC, Baloch ZW, et al. Preoperative diagnosis of benign thyroid nodules with indeterminate cytology. N Engl J Med 2012;367(8):705-15
   PubMed Web of Science ®Google Scholar
• Nikiforova MN, Wald AI, Roy S, et al. Targeted next-generation sequencing panel (ThyroSeq) for detection of mutations in thyroid cancer. J Clin Endocrinol Metab 2013;98(11):E1852-60
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Research Network. Integrated genomic characterization of papillary thyroid carcinoma. Cell 2014;159(3):676-90
   PubMed Web of Science ®Google Scholar
• Damante G, Scaloni A, Tell G. Thyroid tumors: novel insights from proteomic studies. Expert Rev Proteomics 2009;6(4):363-76
   PubMed Web of Science ®Google Scholar
• Megger DA, Pott LL, Ahrens M, et al. Comparison of label-free and label-based strategies for proteome analysis of hepatoma cell lines. Biochim Biophys Acta 2014;1844(5):967-76
   PubMed Web of Science ®Google Scholar
• Coombs KM. Quantitative proteomics of complex mixtures. Expert Rev Proteomics 2011;8(5):659-77
   PubMed Web of Science ®Google Scholar
• Moradian A, Kalli A, Sweredoski MJ, Hess S. The top-down, middle-down, and bottom-up mass spectrometry approaches for characterization of histone variants and their post-translational modifications. Proteomics 2014;14(4-5):489-97
   PubMed Web of Science ®Google Scholar
• Saveliev S, Bratz M, Zubarev R, et al. Trypsin/Lys-C protease mix for enhanced protein mass spectrometry analysis. Nat Methods 2013.10(11). Available from: www.nature.com/nmeth/journal/v10/n11/full/nmeth.f.371.html
   Google Scholar
• Meyer JG, Kim S, Maltby DA, et al. Expanding proteome coverage with orthogonal-specificity α-lytic proteases. Mol Cell Proteomics MCP 2014;13(3):823-35
   PubMed Web of Science ®Google Scholar
• Zhurov KO, Fornelli L, Wodrich MD, et al. Principles of electron capture and transfer dissociation mass spectrometry applied to peptide and protein structure analysis. Chem Soc Rev 2013;42(12):5014-30
   PubMed Web of Science ®Google Scholar
• Nel AJM, Garnett S, Blackburn JM, Soares NC. Comparative Reevaluation of FASP and Enhanced FASP Methods by LC-MS/MS. J Proteome Res 2015;14(3):1637-42
   PubMedGoogle Scholar
• Mainini V, Lalowski M, Gotsopoulos A, et al. MALDI-imaging mass spectrometry on tissues. Methods Mol Biol Clifton NJ 2015;1243:139-64
   PubMedGoogle Scholar
• Balluff B, Frese CK, Maier SK, et al. De novo discovery of phenotypic intratumour heterogeneity using imaging mass spectrometry. J Pathol 2015;235(1):3-13
   PubMed Web of Science ®Google Scholar
• Giusti L, Iacconi P, Ciregia F, et al. Fine-needle aspiration of thyroid nodules: proteomic analysis to identify cancer biomarkers. J Proteome Res 2008;7(9):4079-88
   PubMed Web of Science ®Google Scholar
• Giusti L, Iacconi P, Ciregia F, et al. Proteomic analysis of human thyroid fine needle aspiration fluid. J Endocrinol Invest 2007;30(10):865-9
   PubMedGoogle Scholar
• Ciregia F, Giusti L, Molinaro A, et al. Presence in the pre-surgical fine-needle aspiration of potential thyroid biomarkers previously identified in the post-surgical one. PLoS ONE 2013;8(9):e72911
   Google Scholar
• Mainini V, Pagni F, Garancini M, et al. An alternative approach in endocrine pathology research: MALDI-IMS in papillary thyroid carcinoma. Endocr Pathol 2013;24(4):250-3
   PubMedGoogle Scholar
• Pagni F, Mainini V, Garancini M, et al. Proteomics for the diagnosis of thyroid lesions: preliminary report. Cytopathol Off J Br Soc Clin Cytol 2014. [Epub ahead of print]
   Google Scholar
• Krause K, Schierhorn A, Sinz A, et al. Toward the application of proteomics to human thyroid tissue. Thyroid Off J Am Thyroid Assoc 2006;16(11):1131-43
   PubMedGoogle Scholar
• Berger K, Wissmann D, Ihling C, et al. Quantitative proteome analysis in benign thyroid nodular disease using the fluorescent ruthenium II tris(bathophenanthroline disulfonate) stain. Mol Cell Endocrinol 2004;227(1-2):21-30
   PubMedGoogle Scholar
• Lin JD, Huang CC, Weng HF, et al. Comparison of membrane proteins from benign and malignant human thyroid tissues by two-dimensional polyacrylamide gel electrophoresis. J Chromatogr B Biomed Appl 1995;667(1):153-60
   PubMedGoogle Scholar
• Lin JD, Chan EC, Weng HF, Sheu CA. Two-dimensional electrophoretic analysis of membranous protein from human thyroid tissues and cancer cell lines. Electrophoresis 1998;19(18):3213-16
   PubMedGoogle Scholar
• Krause K, Karger S, Schierhorn A, et al. Proteomic profiling of cold thyroid nodules. Endocrinology 2007;148(4):1754-63
   PubMedGoogle Scholar
• Brown LM, Helmke SM, Hunsucker SW, et al. Quantitative and qualitative differences in protein expression between papillary thyroid carcinoma and normal thyroid tissue. Mol Carcinog 2006;45(8):613-26
   PubMedGoogle Scholar
• Torres-Cabala C, Bibbo M, Panizo-Santos A, et al. Proteomic identification of new biomarkers and application in thyroid cytology. Acta Cytol 2006;50(5):518-28
   PubMedGoogle Scholar
• Puxeddu E, Susta F, Orvietani PL, et al. Identification of differentially expressed proteins in papillary thyroid carcinomas with V600E mutation of BRAF. Proteomics Clin Appl 2007;1(7):672-80
   PubMedGoogle Scholar
• Netea-Maier RT, Hunsucker SW, Hoevenaars BM, et al. Discovery and validation of protein abundance differences between follicular thyroid neoplasms. Cancer Res 2008;68(5):1572-80
   PubMedGoogle Scholar
• Sofiadis A, Becker S, Hellman U, et al. Proteomic profiling of follicular and papillary thyroid tumors. Eur J Endocrinol Eur Fed Endocr Soc 2012;166(4):657-67
   PubMedGoogle Scholar
• Park WS, Chung KW, Young MS, et al. Differential protein expression of lymph node metastases of papillary thyroid carcinoma harboring the BRAF mutation. Anticancer Res 2013;33(10):4357-64
   PubMedGoogle Scholar
• Suriano R, Lin Y, Ashok BT, et al. Pilot study using SELDI-TOF-MS based proteomic profile for the identification of diagnostic biomarkers of thyroid proliferative diseases. J Proteome Res 2006;5(4):856-61
   PubMedGoogle Scholar
• Sofiadis A, Dinets A, Orre LM, et al. Proteomic study of thyroid tumors reveals frequent up-regulation of the Ca2+ -binding protein S100A6 in papillary thyroid carcinoma. Thyroid Off J Am Thyroid Assoc 2010;20(10):1067-76
   PubMedGoogle Scholar
• Meding S, Nitsche U, Balluff B, et al. Tumor classification of six common cancer types based on proteomic profiling by MALDI imaging. J Proteome Res 2012;11(3):1996-2003
   PubMed Web of Science ®Google Scholar
• Nipp M, Elsner M, Balluff B, et al. S100-A10, thioredoxin, and S100-A6 as biomarkers of papillary thyroid carcinoma with lymph node metastasis identified by MALDI imaging. J Mol Med Berl Ger 2012;90(2):163-74
   PubMed Web of Science ®Google Scholar
• Min KW, Bang JY, Kim KP, et al. Imaging mass spectrometry in papillary thyroid carcinoma for the identification and validation of biomarker proteins. J Korean Med Sci 2014;29(7):934-40
   PubMed Web of Science ®Google Scholar
• Ishikawa S, Tateya I, Hayasaka T, et al. Increased expression of phosphatidylcholine (16:0/18:1) and (16:0/18:2) in thyroid papillary cancer. PLoS ONE 2012;7(11):e48873
   PubMed Web of Science ®Google Scholar
• De Sio G, Smith AJ, Galli M, et al. A MALDI-mass spectrometry imaging method applicable to different formalin-fixed paraffin-embedded human tissues. Mol Biosyst 2015;11(6):1507-14
   PubMed Web of Science ®Google Scholar
• Heitzer E, Ulz P, Geigl JB. Circulating tumor DNA as a liquid biopsy for cancer. Clin Chem 2015;61(1):112-23
   PubMed Web of Science ®Google Scholar
• Lianidou ES, Strati A, Markou A. Circulating tumor cells as promising novel biomarkers in solid cancers. Crit Rev Clin Lab Sci 2014;51(3):160-71
   PubMed Web of Science ®Google Scholar
• Villanueva J, Martorella AJ, Lawlor K, et al. Serum peptidome patterns that distinguish metastatic thyroid carcinoma from cancer-free controls are unbiased by gender and age. Mol Cell Proteomics MCP 2006;5(10):1840-52
   PubMedGoogle Scholar
• Villanueva J, Nazarian A, Lawlor K, et al. A sequence-specific exopeptidase activity test (SSEAT) for “functional” biomarker discovery. Mol Cell Proteomics MCP 2008;7(3):509-18
   PubMedGoogle Scholar
• Song HJ, Xue YL, Qiu ZL, Luo QY. Comparative serum proteomic analysis identified afamin as a downregulated protein in papillary thyroid carcinoma patients with non-131I-avid lung metastases. Nucl Med Commun 2013;34(12):1196-203
   PubMed Web of Science ®Google Scholar
• Xu YH, Wang WJ, Song HJ, et al. Serum differential proteomics analysis between papillary thyroid cancer patients with 131I-avid and those with non-131I-avid lung metastases. Hell J Nucl Med 2011;14(3):228-33
   PubMedGoogle Scholar
• Wang JX, Yu JK, Wang L, et al. Application of serum protein fingerprint in diagnosis of papillary thyroid carcinoma. Proteomics 2006;6(19):5344-9
   PubMedGoogle Scholar
• Moretz WH, Gourin CG, Terris DJ, et al. Detection of papillary thyroid carcinoma with serum protein profile analysis. Arch Otolaryngol Head Neck Surg 2008;134(2):198-202
   PubMedGoogle Scholar
• Fan Y, Shi L, Liu Q, et al. Discovery and identification of potential biomarkers of papillary thyroid carcinoma. Mol Cancer 2009;8:79
   PubMedGoogle Scholar
• Linkov F, Ferris RL, Yurkovetsky Z, et al. Multiplex analysis of cytokines as biomarkers that differentiate benign and malignant thyroid diseases. Proteomics Clin Appl 2008;2(12):1575-85
   PubMed Web of Science ®Google Scholar
• Musso R, Di Cara G, Albanese NN, et al. Differential proteomic and phenotypic behaviour of papillary and anaplastic thyroid cell lines. J Proteomics 2013;90:115-25
   PubMedGoogle Scholar
• Chaker S, Kashat L, Voisin S, et al. Secretome proteins as candidate biomarkers for aggressive thyroid carcinomas. Proteomics 2013;13(5):771-87
   PubMed Web of Science ®Google Scholar
• Li X, Wang Z, Liu J, et al. Proteomic analysis of differentially expressed proteins in normal human thyroid cells transfected with PPFP. Endocr Relat Cancer 2012;19(5):681-94
   PubMedGoogle Scholar
• Minuto MN, Shintu L, Caldarelli S. Proteomics, and metabolomics: magnetic resonance spectroscopy for the presurgical screening of thyroid nodules. Curr Genomics 2014;15(3):178-83
   PubMedGoogle Scholar
• Jordan KW, Adkins CB, Cheng LL, Faquin WC. Application of magnetic-resonance-spectroscopy- based metabolomics to the fine-needle aspiration diagnosis of papillary thyroid carcinoma. Acta Cytol 2011;55(6):584-9
   PubMedGoogle Scholar
• Torregrossa L, Shintu L, Nambiath Chandran J, et al. Toward the reliable diagnosis of indeterminate thyroid lesions: a HRMAS NMR-based metabolomics case of study. J Proteome Res 2012;11(6):3317-25
   PubMedGoogle Scholar